MetaCap

Bionano Genomics Inc. Company Profile

NASDAQ: BNGOIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

1.48+0.02 (+1.37%)

Market open · Delayed 15 min · as of Oct 9, 11:24 AM ET

Bionano Genomics at a glance

Bionano Genomics Inc. (NASDAQ: BNGO) is a Biotechnology: Laboratory Analytical Instruments company in the Industrials sector headquartered in San Diego, CA. Bionano Genomics is led by Dr. Albert A. Luderer Ph.D. and employs about 95 people. The company's shares have traded publicly since 2018.

At a market capitalization of $17.2 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001411690, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Bionano Genomics do?

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Business description based on the company's public filings.

Company information

Legal name
Bionano Genomics Inc.
Ticker
NASDAQ: BNGO
Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Dr. Albert A. Luderer Ph.D.
Employees
95
Headquarters
9540 Towne Centre Drive, San Diego, CA, United States
Phone
858 888 7600
IPO year
2018
Market cap
$17.19M
SEC CIK
0001411690
Latest annual report
10-K · Mar 23, 2026

Companies similar to Bionano Genomics

BNGO peer companies
CompanyPrice% ChgMarket capCompare
ASTCAstrotech Corporation (DE)6.92+1.17%$14.54Mvs BNGO
HBIOHarvard Bioscience Inc.8.16+0.32%$37.13Mvs BNGO
PRPOPrecipio Inc.23.27+0.33%$41.65Mvs BNGO
RPIDRapid Micro Biosystems Inc. Class A0.8917+3.45%$44.73Mvs BNGO
CIRCCircle8 Group Inc.0.4779+7.17%$56.15Mvs BNGO
SEERSeer Inc. Class A2.23+2.54%$123.20Mvs BNGO
QTRXQuanterix Corporation3.29+2.49%$155.59Mvs BNGO
NAUTNautilus Biotechnology Inc.1.99+9.34%$253.24Mvs BNGO

Related